Navigation Links
UVA reports surprising findings related to myotonic muscular dystrophy
Date:12/17/2007

s are intermediary molecules that convey the genetic code in the DNA to the rest of the cell. RNAs are normally cut and pasted together by a process called RNA splicing. It is currently thought that the toxic RNA causes DM1 by disrupting normal RNA splicing.

Much of the research on DM1 is focused on factors that cause RNA splicing defects. Our work may provide explanations for pathogenic effects not accounted for by RNA mis-splicing, Mahadevan explained.

In this current study, Dr. Mahadevan and his colleagues built upon their groundbreaking research from 2006 which showed that toxic RNA causes DM1 and that getting rid of it actually reversed the disease process. Their latest findings demonstrate a new effect of RNA toxicity and how this may cause cardiac conduction abnormalities.


'/>"/>

Contact: Ellen McKenna
ecm6n@virginia.edu
434-982-4490
University of Virginia Health System
Source:Eurekalert

0

GOOD

Page: 1 2

Related biology news :

1. BIO-key Reports Second Quarter 2007 Results
2. Communication Intelligence Corporation Reports Second Quarter 2007 Financial Results
3. Emory paleontologist reports discovery of carnivorous dinosaur tracks in Australia
4. BIO-key Reports Third Quarter 2007 Results
5. WHRC releases 4 key reports
6. Rong Li Lab reports protein interactions of MAP kinase signaling pathway
7. European Union forests expanding, absorbing carbon at surprisingly high rate: study
8. The surprising story of Charles Darwin and his homeopathic doctor
9. New prostate cancer research findings
10. K-State researchers findings on E. coli
11. Claims of sex-related differences in genetic association studies often not properly validated
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Munich lab demonstrates diesel truck engine with barely measurable emissions 2Munich lab demonstrates diesel truck engine with barely measurable emissions 3Texas AgriLife researchers helping 2Texas AgriLife researchers helping 3Texas AgriLife researchers helping 4Study Finds Noninvasive Blood Test for Liver Fibrosis May Alleviate Need for Liver Biopsies for Some Patients with Chronic Hepatitis C 12523 1Study Finds Noninvasive Blood Test for Liver Fibrosis May Alleviate Need for Liver Biopsies for Some Patients with Chronic Hepatitis C 12523 2Study Finds Noninvasive Blood Test for Liver Fibrosis May Alleviate Need for Liver Biopsies for Some Patients with Chronic Hepatitis C 12523 3Study Finds Noninvasive Blood Test for Liver Fibrosis May Alleviate Need for Liver Biopsies for Some Patients with Chronic Hepatitis C 12523 4Women underrepresented in most cancer research 48173 1Women underrepresented in most cancer research 48173 2Women underrepresented in most cancer research 48173 3Women underrepresented in most cancer research 48173 4American Chemical Societys Weekly PressPac June 3 2009 8740 1American Chemical Societys Weekly PressPac June 3 2009 8740 2American Chemical Societys Weekly PressPac June 3 2009 8740 3American Chemical Societys Weekly PressPac June 3 2009 8740 4American Chemical Societys Weekly PressPac June 3 2009 8740 5American Chemical Societys Weekly PressPac June 3 2009 8740 6American Chemical Societys Weekly PressPac June 3 2009 8740 7American Chemical Societys Weekly PressPac June 3 2009 8740 8American Chemical Societys Weekly PressPac June 3 2009 8740 9American Chemical Societys Weekly PressPac June 3 2009 8740 10
Breaking Biology Technology:AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 2Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 3Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 4WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening 2Alberta companies delivering new products to the health & medical marketplace 2